News

Roger A. Goldberg, MD, MBA, notes how small misalignments in the plunger can lead to possible overdosing.

Denise Freitas, MD, reports on ocular findings in infants with congenital Zika virus syndrome that were similar among the affected infants and occurred frequently.

Felipe Medeiros, MD, presents results from a phase 3 clinical extension study of the bimatoprost implant that found patients’ IOP was lowered and stayed low with no additional treatment or changes in their visual fiends.

Shady Awwad, MD, discusses how the application of mitomycin C after corneal crosslinking does not prevent development of corneal haze after the procedure and actually contributes to development of more corneal haze.

Gareth Lema, MD, PhD, spotlights a treatment could provide benefits for patients with central retinal artery occlusion.

The results are in! Check out how your institution ranked in the 2021 Ophthalmology Times® Best Program Survey.

Bausch + Lomb's Yolande Barnard, shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis.

Dilsher Dhoot, MD, reports results of the KESTREL and KITE trials, in which brolucizumab was compared with aflibercept for treating diabetic macular edema.

“Real talk” on new devices gives surgeons, patients decision-making insights

Investigators from the University of Maryland found that uncovering the mechanism of vision loss in Usher syndrome yields additional drug targets for eventual development of better therapies.

Ophthalmologist outlines his journey with the procedure as a late adopter.

According to a team of investigators in Israel, after a third dose of the Pfizer-BioNTech COVID-19 vaccine, the antibody titers increased significantly in individuals over the age of 60.

Unity Biotechnology announces improvement in visual acuity sustained through 24 weeks following single dose of UBX1325 in Phase 1 study of patients with advanced vascular eye disease.

Alcon this week announced its plans to acquire glaucoma surgery device maker Ivantis Inc. in a $475 million deal.

Retinal and choroidal changes were observed in study.

Procedure transfers intact donor nerve fibers to the cornea.

In light of newly published fee schedules that include low payment rates for LipiFlow, Cynthia Matossian, MD, FACS, ABES, advises on how eyecare professionals should advocate for their patients and practices.

Targeted antibody testing and therapy offers new options for ophthalmologists

Perspectives from a pediatric ophthalmologist and mother.

Pilot study tests the technology to obtain remote fundus imaging of patients.

Investigators find that mutations could lead to early treatment intervention.

Organizations are urging consumers to be aware of insurance policies that can limit their access to sight-saving procedures and treatments.

Staying current on phaco technology can help surgeons provide better outcomes.

Aldeyra Therapeutics announced today that it has achieved the primary endpoint of ocular redness in its randomly assigned, double-masked, vehicle-controlled Phase 2 clinical trial in dry eye disease.

The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).

Allergan developed VUITY, which it noted is the first and only FDA-approved eye drop to treat presbyopia.

Investigators in Australia are developing a new rapid screening test for glaucoma that could help advance early detection of the disease.

The Cleveland Clinic named Rishi Singh, MD, president of the Cleveland Clinic Martin North and South hospitals in Martin County, Florida.